Studies have shown that therapies targeting HMGB1 have significant effects in Alzheimer’s disease models, reducing neurodegeneration and improving cognitive function (Paudel et al., 2020). This evidence concerns the gene HMGB1 and early-onset autosomal dominant Alzheimer disease.